Abstract
Recently, numerous cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) have been reported. Patients who receive oral bisphosphonate therapy are at a considerably lower risk for BRONJ than those who receive intravenous bisphosphonate formulations. However, because several cases of BRONJ have been related to oral bisphosphonates, dentists should cautiously perform oral surgical procedures. The American Association of Oral and Maxillofacial Surgeons recommends that the placement of dental implants is avoided in patients who are receiving bisphosphonates intravenously according to a frequent dosing schedule.
We describe the placement of dental implants in a patient who was receiving an oral bisphosphonate (risedronate) to treat osteoporosis. We obtained written informed consent from the patient before surgery. After discontinuing the drug for 2 months before implant surgery, 2 dental implant were placed in the mandible. The implants were successfully integrated and are functioning well.
